In Cell Art

Unlocking the promise of nucleic acids to treat diseases using Nanotaxi®
Regenerative Medicine

General activities

A fully integrated group focused on scientific researc.

In-Cell-Art, is a biopharmaceutical company specializing in the preclinical and pharmaceutical development of solution (DNA/RNA based vaccines or therapeutics) treating acquired or inherited diseases using patented bioinspired synthetic delivery systems (named Nanotaxi®).


Its founder and research team, which includes a Nobel Laureate, have developed this unique intellectual property expertise and know-how based on 20 years of research in the field of supramolecular nucleic acids transfection agents.


The vaccines and therapeutics developed by In-Cell-Art have been validated by numerous studies using infectious disease models (HIV, Flu, Dengue, dust mite, mycobacterium abscessus), therapeutic cancer models (melanoma, liver, breast and cervical cancers) and therapeutic models (muscular dystrophy, anemia in kidney failure)


In-Cell-Art has recently advanced vaccines into regulatory preclinical studies for human clinical trials and shown promising safety and immunogenicity profiles.

Terms of collaboration

☒ Research collaboration
☒ Service provision

☒ Material supply

☒ Co-development

☒ Other

Is affiliated to the cluster